Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Nanoparticles may be used to make safer and more effective RNA-based therapeutics

A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with these therapies and the use of lipid-based nanoparticles may offer a safer alternative, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “RNA has received considerable research attention in recent years and has the […]
Read more

Nanotechnology being used by researchers in fight against COVID-19

With the accelerating global burden from the COVID-19 pandemic, researchers are rapidly searching for a viable vaccine or therapeutic to combat the global public health emergency. One of the approaches being investigated is the use of nanotechnology, says GlobalData, a leading data and analytics company. An international collaboration has developed a nanotechnology approach to halting […]
Read more

Novartis’ Isturisa provides new hope to Cushing’s disease market

Novartis’ Isturisa (osilodrostat) leads recent innovation in Cushing’s disease (CD) with its latest Food and Drug Administration (FDA) approval, says GlobalData, a leading data and analytics company. Isturisa, an 11-beta-hydroxylase inhibitor, is the first FDA approved drug to directly target overproduction of cortisol, the hormone of issue in CD. The drug has proven to be […]
Read more

Government initiatives minimize Indian pharma industry manufacturing and supply chain disruptions amid Covid-19 crisis, says GlobalData

India’s coronavirus (Covid-19) lockdown has impacted the manufacturing and supply chain operations of pharmaceuticals despite pharmaceutical manufacturing being considered an essential service and excluded from the lockdown. However, government initiatives have helped to minimize disruptions to pharmaceutical manufacturing and the supply chain, says GlobalData, a leading data and analytics company. The issues faced by the […]
Read more

Global age-related macular degeneration market will more than double in size by 2028

The pharmaceutical market for age-related macular degeneration (AMD) was worth an estimated $8.6bn across the nine major markets (9MM*) in 2018. This is expected to grow to $18.7bn in 2028 at a modest compound annual growth rate (CAGR) of 8.1%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028’, explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch […]
Read more

Healthcare sector witnesses decline in deal activity during the week ended April 12

The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 28% during the week ended April 12, 2020 compared to the previous week, according to GlobalData’s deals database. Aurojyoti Bose, Analyst at GlobalData, comments: “The decline was subsequent to two consecutive weeks of growth in deal activity. Deal activity in the healthcare sector has remained inconsistent due to uncertainty and volatile market conditions since the coronavirus outbreak.” Deal activity declined in the key markets such as the US and China during the week ended April 12. The announcement of venture financing, partnership, licensing agreement and merger and […]
Read more

Protease inhibitors could benefit from being trialled with milder cases of COVID-19

AbbVie was one of the first companies to donate its combination of HIV protease inhibitors Aluvia (lopinavir/ritonavir), also known as Kaletra, to help China treat patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, more recent investigations show that treatment with lopinavir-ritonavir does not actually provide a substantial benefit beyond standard care*, says GlobalData, a leading data and analytics company. Angad Lotay, MPharm, Infectious Diseases Analyst at GlobalData, […]
Read more

Rheumatology patients treatment jeopardized by coronavirus pandemic

With the global COVID-19 pandemic, many patient groups are at an increased risk of infection and this extends to rheumatology patients prescribed immunosuppressant medication. The outbreak has presented these patients with medical and logistical difficulties that will certainly jeopardize their treatment, says GlobalData, a leading data and analytics company.  Antoine Grey, MBiochem, Senior Healthcare Analyst […]
Read more

AstraZeneca gains approval for Koselugo in rare neurological disorder after 17 years of development

Following the news that AstraZeneca’s Koselugo (selumetinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of a rare neurological disorder; Philippa Salter, Neurology & Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Previous treatments for neurofibromatosis type 1 (NF1) in pediatric patients, who have […]
Read more

Fujifilm’s influenza drug favipiravir being tested to treat COVID-19

As the number of confirmed COVID-19 cases reaches nearly 1.5 million worldwide, with almost 430,000 in the US alone, the urgency of finding a treatment mounts. One of the potentially quickest ways to find treatment is to test drugs already approved or in development for other indications, says GlobalData, a leading data and analytics company. Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData commented: […]
Read more

Increased availability of virtual mental health tools reported as the COVID-19 crisis continues

Use of virtual mental health tools is expected to rise significantly over the coming months as self-quarantine and social distancing measures show no signs of being lifted, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “COVID-19 has placed enormous strain on the mental health of the general public, as well as healthcare professionals. The crisis is causing heightened anxiety and stress, with people feeling vulnerable and struggling with worries about contracting the virus, job losses and pay […]
Read more

Novo Nordisk’s dominance in GLP-1RA market to continue with arrival of Rybelsus and strong sales for Ozempic in 2019

Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel MSc, Pharma Analyst at GlobalData, comments: “Ozempic (semaglutide) is an injectable GLP-1RA indicated for the treatment of type 2 diabetes (T2D). Since its US launch in February 2018, the drug’s market share has grown due to its impressive glycemic and non-glycemic benefits. The drug also […]
Read more

Biomarkers heavily used as diagnostic tools in COVID-19 trials

Biomarkers are a beneficial tool in the search for a COVID-19 vaccine and will help speed up clinical trials, reduce costs of development, guide subject selection, reduce patient safety risks and allow for easier verification of the mechanism of action, says GlobalData, a leading data and analytics company. According to GlobalData’s Biomarkers database, the top […]
Read more

Novartis digital initiatives to create awareness of heart failure can positively impact patients’ lives in India, says GlobalData

Novartis has taken a lead in actively promoting heart failure awareness across India through unbranded digital initiatives that can successfully deliver message to a large population at risk, says GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center, the diagnosed prevalence of congestive heart failure in India is currently around 9.61 […]
Read more

COVID-19 pandemic affects development of Alzheimer’s drugs

With many countries putting clinical trials studies on hold, pharmaceutical companies are shifting their overall priorities away from some current indications toward COVID-19. This could put several Alzheimer’s Disease (AD) drugs, of which there are 38 in Phase I, 19 in Phase III and 37 in Phase II, at risk of delay, says GlobalData, a leading data and […]
Read more

COVID-19 exposes fragility of global supply chains but blockchain could be missing link in building resilience, says GlobalData

The COVID-19 pandemic has disrupted nearly every part of supply chains within the healthcare industry, once again exposing the vulnerabilities of many organizations, especially those that have a high dependence on markets such as India and China to meet their raw materials or finished products’ needs. The COVID-19 outbreak is likely to result in healthcare […]
Read more

Clinical trials delayed during COVID-19, says GlobalData

There has been an increase in clinical trial delays due to concerns for patient and investigator safety, travel restrictions, subject quarantine, clinical site closures and interrupted supply chains. Numerous aspects of clinical trials are being impacted including enrolment of patients, study start times and initiation of new studies, says GlobalData, a leading data and analytics […]
Read more
1 … 96 97 98 99 100 … 108